Human leukocyte antigen-G isoform HLA-G2/6, but not HLA-G1/4/5, is an independent indicator of poor survival in patients with colorectal cancer
Guardado en:
| Publicado en: | Frontiers in Immunology vol. 16 (Oct 2025), p. 1672144-1672158 |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , |
| Publicado: |
Frontiers Media SA
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3278326296 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1664-3224 | ||
| 024 | 7 | |a 10.3389/fimmu.2025.1672144 |2 doi | |
| 035 | |a 3278326296 | ||
| 045 | 2 | |b d20251001 |b d20251031 | |
| 100 | 1 | |a Zhang, Xia |u Biological Resource Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Key Laboratory of Human Leukocyte antigen - G (HLA-G) Research & Development of Taizhou, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 245 | 1 | |a Human leukocyte antigen-G isoform HLA-G2/6, but not HLA-G1/4/5, is an independent indicator of poor survival in patients with colorectal cancer | |
| 260 | |b Frontiers Media SA |c Oct 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a BackgroundHuman leukocyte antigen (HLA)-G has multiple isoforms with unique molecular structures and receptor-binding specificities. Different HLA-G isoform(s) may have distinct clinical relevance. Because of the lack of isoform-specific monoclonal antibodies (mAbs), the clinical significance of HLA-G isoforms (HLA-G1 to HLA-G7), except HLA-G1 and HLA-G5, remains largely unknown.MethodsIn this study, mAbs against HLA-G2/6 and HLA-G1/4/5 isoforms were generated and characterized. Expression of HLA-G2/6 and HLA-G1/4/5 isoforms was analyzed by immunohistochemistry, and clinical significance was evaluated retrospectively in 345 patients with colorectal cancer (CRC).ResultsThe expression rate of HLA-G2/6 (90/345, 26.1%) was significantly lower than that of HLA-G1/4/5 (275/345, 79.7%; p < 0.001). Patients with HLA-G2/6 expression had significantly poorer overall survival (OS) (median OS: 6.3 years [95% CI: 4.1–8.5] vs . 10.0 years [95% CI: 7.6–12.4]; p = 0.008). Multivariate Cox proportional-hazard model results indicated that HLA-G2/6 was an independent prognostic factor for CRC (hazard ratio [HR] = 1.530, 95% CI: 1.125–2.081; p = 0.007). Moreover, HLA-G2/6 expression showed stratified prognostic significance among several CRC patient subgroups, specifically in female patients (p = 0.003), younger patients (<66 years p < 0.001), patients with colon cancer ( p = 0.045), those at stage pT3 ( p = 0.008), pN1 ( p = 0.020), p M0 ( p = 0.009), and AJCC stage III ( p = 0.005). However, no statistical significance was found between HLA-G1/4/5 isoform expression and patient prognosis in CRC.ConclusionsThis is the first study to generate mAbs for the HLA-G2/6 and HLA-G1/4/5 isoforms. Our findings reveal that HLA-G2/6—but not HLA-G1/4/5—expression is an independent prognostic indicator for patients with CRC. In the context of precision medicine, our study also suggests that HLA-G isoform typing may be necessary for HLA-G-targeted cancer immunotherapy. | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a Shanghai China | |
| 651 | 4 | |a China | |
| 651 | 4 | |a Zhejiang China | |
| 653 | |a Monoclonal antibodies | ||
| 653 | |a Metastasis | ||
| 653 | |a Precision medicine | ||
| 653 | |a Immunotherapy | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Leukocytes | ||
| 653 | |a Isoforms | ||
| 653 | |a Ethics | ||
| 653 | |a Peptides | ||
| 653 | |a Colorectal cancer | ||
| 653 | |a Colon cancer | ||
| 653 | |a Clinical significance | ||
| 653 | |a Cancer immunotherapy | ||
| 653 | |a Laboratory animals | ||
| 653 | |a Patients | ||
| 653 | |a Tissue typing | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Cloning | ||
| 653 | |a Histocompatibility antigen HLA | ||
| 653 | |a Immune response | ||
| 653 | |a Immunohistochemistry | ||
| 653 | |a Hospitals | ||
| 653 | |a Committees | ||
| 653 | |a Colorectal carcinoma | ||
| 653 | |a Antigens | ||
| 700 | 1 | |a Qiu-Yue, Han |u Biological Resource Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Key Laboratory of Human Leukocyte antigen - G (HLA-G) Research & Development of Taizhou, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 700 | 1 | |a Zhang, Jian-Gang |u Biological Resource Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 700 | 1 | |a Jiao, Lin |u Department of Urology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 700 | 1 | |a Wei-Hua, Yan |u Key Laboratory of Human Leukocyte antigen - G (HLA-G) Research & Development of Taizhou, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 700 | 1 | |a Lin, Aifen |u Biological Resource Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Key Laboratory of Human Leukocyte antigen - G (HLA-G) Research & Development of Taizhou, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China | |
| 773 | 0 | |t Frontiers in Immunology |g vol. 16 (Oct 2025), p. 1672144-1672158 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3278326296/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3278326296/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3278326296/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |